𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Trimetrexate in untreated and previously treated patients with metastatic breast cancer: A cancer and leukemia group b study

✍ Scribed by Dawson, Nancy A. ;Costanza, Mary E. ;Korzun, Ann H. ;Clamon, Gerald H. ;Pollak, Michael ;Vogelzang, Nicholas J. ;Carey, Robert W. ;Norton, Larry

Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
554 KB
Volume
19
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Twenty-two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX). Patients received TMTX 8 mg/m2/day if previously treated or 12 mg/m2/day if previously untreated, both given by intravenous bolus days 1-5, every 21 days. None of the patients previously treated for metastatic disease responded to TMTX. There was one partial responder among the 22 patients with previously untreated metastatic disease. The primary toxicity was hematologic and occurred more frequently in patients with a pleural effusion, low serum protein or albumin, or poor performance status. There were three toxic deaths. The study for previously untreated patients required cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) after 4 cycles of TMTX. This study design for previously untreated patients allows the Cancer and Leukemia Group B (CALGB) to prospectively evaluate the activity of new agents in "chemotherapy-sensitive" metastatic breast cancer.

πŸ“œ SIMILAR VOLUMES

Panitumumab monotherapy in patients with
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
✍ J. Randolph Hecht; Amita Patnaik; Jordan Berlin; Alan Venook; Imtiaz Malik; Simo πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 237 KB

## Abstract ## BACKGROUND. The safety and efficacy of the fully human antibody panitumumab was evaluated in patients with metastatic colorectal cancer refractory to available therapies. ## METHODS. This phase 2 open‐label, multicenter study of panitumumab enrolled patients with metastatic colore

Phase II trial of ifosfamide and mesna i
Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8552
✍ Case, Delvyn C. ;Anderson, James ;Ervin, Thomas J. ;Gottlieb, Arlan πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 481 KB

Ifosfamide (1.25 g/m2 intravenously/day x 5) with mesna (20% of the ifosfamide dose x six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non-Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29% response rate (9/31) was observed (2 CR and

Phase II trial of ifosfamide and mesna i
Phase II trial of ifosfamide and mesna in previously treated patients with non-hodgkin's lymphoma: Cancer and leukemia group b study 8552
✍ Delvyn C. Case JR; James Anderson; Thomas J. Ervin; Arlan Gottlieb πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 522 KB

## Abstract Ifosfamide (1Β·25 g/m^2^ intravenously/day Γ— 5) with mesna (20 per cent of the ifosfamide dose Γ— six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non‐Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29 per cent response rat

Phase II trial of ifosfamide/mesna and m
Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8753
✍ Case, Delvyn C. ;Santarelli, Maria Teresa ;Carey, Robert W. ;Anderson, James ;Go πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 461 KB

## Abstract Ifosfamide (2.0 g/m^2^ intravenously/day Γ— 3) with mesna (400 mg/m^2^ intravenously q 4 h daily Γ— 3) was combined with mitoxantrone (14 mg/m^2^ intravenously Γ— 1) and given on a 3 week schedule to patients with previously treated non‐Hodkgin's lymphoma. In 45 eligible/evaluable patients